Analytical Data
-
Gene name
EIF2S1
- Application
-
Alternative Names
EIF-2; EIF-2A; EIF-2alpha; EIF2; EIF2A; Eukaryotic translation initiation factor 2 subunit alpha
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P05198
-
Expression Region
Met1~Thr239
-
Molecular Weight
33kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
EIF2S1, also known as eukaryotic translation initiation factor 2 subunit alpha (eIF2α), plays a crucial role in the regulation of protein synthesis and cellular stress responses. It is a pivotal component of the translation initiation machinery, facilitating the binding of initiator tRNA to the ribosome. Research into the recombinant expression of EIF2S1 has gained momentum due to its implications in various biological processes and disease states, particularly in cancer and neurodegenerative disorders. Abnormal phosphorylation of eIF2α is a common feature in many forms of stress and pathology, leading to altered translational control and cell survival mechanisms. Recombinant EIF2S1 can be utilized to study the structure-function relationships of this protein, investigate its interactions with various translational and stress response factors, and unravel the mechanisms through which it influences cell fate. Additionally, producing EIF2S1 in a recombinant form allows for the development of therapeutic strategies aimed at modulating its activity, thereby opening new avenues for treatment in diseases characterized by dysregulated protein synthesis. As such, research on recombinant EIF2S1 not only furthers our understanding of fundamental cellular processes but also holds potential for innovative therapeutic interventions.
